Related Experiment Video
Updated: Jan 16, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
845
Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells
Yalda Hekmatshoar1, Tulin Ozkan2, Arzu Zeynep Karabay3
1Department of Medical Biology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey.
Biomolecules
|September 27, 2025
Summary
Targeting integrin alpha 2 (ITGA2) may overcome imatinib resistance in chronic myeloid leukemia (CML). Inhibiting ITGA2 with E7820 reduced cell viability and induced apoptosis, offering a new CML treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Hematology
Background:
- Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion gene.
- Imatinib resistance is a significant challenge in CML treatment.
- Integrin alpha 2 (ITGA2) is implicated in cancer progression and drug resistance.
Purpose of the Study:
- To investigate the role of ITGA2 in imatinib resistance in CML.
- To evaluate the efficacy of an ITGA2 inhibitor (E7820) in overcoming imatinib resistance.
Main Methods:
- Utilized imatinib-sensitive (K562S) and resistant (K562R) CML cell lines.
- Treated cells with ITGA2 inhibitor E7820, imatinib, or combination therapy.
- Assessed cell viability, apoptosis, gene expression (BAX, BIM, BCL2), protein levels, and MDR1 activity.
Main Results:
- ITGA2 was overexpressed in imatinib-resistant K562R cells.
- E7820 treatment reduced cell viability and induced apoptosis in both sensitive and resistant cells.
- Combination therapy enhanced pro-apoptotic gene expression and reduced anti-apoptotic gene expression in resistant cells, also decreasing MDR1 activity.
Conclusions:
- ITGA2 overexpression contributes to imatinib resistance in CML.
- Targeting ITGA2 with E7820 shows potential to overcome imatinib resistance.
- ITGA2 inhibition presents a novel therapeutic strategy for CML patients resistant to imatinib.
Related Concept Videos
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:17Intracellular Signaling Affects Focal Adhesions
3.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.5K
01:15Activation of Integrins
4.9K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.9K